Kam Sprott, PhD (she/her/hers)

Executive Director of Translational Medicine
Deciphera Pharmaceuticals, LLC
Waltham, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• Paper 61 - INSIGHT: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR PREVIOUSLY TREATED WITH IMATINIB WITH KIT EXON 11+17/18 MUTATIONS

  Saturday, November 4, 2023
  9:00 AM – 10:00 AM